Symbols / IMVT Stock $30.82 -6.21% Immunovant, Inc.
IMVT (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteImmunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Ratings
Current target
$30.82
Low
$24.00
High
$66.00
Mean
$45.76
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-26 | main | Guggenheim | Buy → Buy | $62 |
| 2026-05-22 | main | Truist Securities | Hold → Hold | $30 |
| 2026-05-21 | main | B of A Securities | Buy → Buy | $43 |
| 2026-05-21 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2026-04-15 | main | Goldman Sachs | Neutral → Neutral | $32 |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2026-02-09 | main | Guggenheim | Buy → Buy | $44 |
| 2026-01-08 | main | Truist Securities | Hold → Hold | $22 |
| 2026-01-06 | up | Wolfe Research | Peer Perform → Outperform | $50 |
| 2025-12-15 | main | Goldman Sachs | Neutral → Neutral | $28 |
| 2025-10-14 | init | Truist Securities | — → Hold | $16 |
| 2025-09-30 | main | JP Morgan | Overweight → Overweight | $33 |
| 2025-09-04 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-08-12 | main | JP Morgan | Overweight → Overweight | $37 |
| 2025-08-12 | main | B of A Securities | Buy → Buy | $30 |
| 2025-07-28 | main | UBS | Neutral → Neutral | $18 |
| 2025-04-22 | down | UBS | Buy → Neutral | $17 |
| 2025-03-20 | reit | Guggenheim | Buy → Buy | — |
| 2025-03-20 | main | B of A Securities | Buy → Buy | $33 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $51 |
- H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data - Yahoo Finance ue, 02 Jun 2026 09
- Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo Fri, 29 May 2026 23
- Assessing Immunovant (IMVT) Valuation After Strong Recent Share Price Momentum - simplywall.st Fri, 29 May 2026 16
- [144] Immunovant, Inc. SEC Filing - Stock Titan hu, 28 May 2026 20
- IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN Sun, 31 May 2026 01
- These Two Biotech Stocks Rocketed — And One Just Broke Out - Investor's Business Daily Wed, 20 May 2026 07
- IMMUNOVANT ($IMVT) Releases Q4 2026 Earnings - Quiver Quantitative Wed, 20 May 2026 07
- Immunovant: Best-In-Class Ambitions, Still Unproven (NASDAQ:IMVT) - Seeking Alpha Mon, 20 Apr 2026 07
- Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options - Stock Titan Fri, 29 May 2026 20
- Roivant Sciences (ROIV) Valuation After Strong IMVT-1402 Data And Late Stage Pipeline Momentum - simplywall.st Fri, 29 May 2026 15
- Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating - Yahoo Finance hu, 28 May 2026 11
- New Immunovant drug posts 72.7% response rate in tough arthritis cases - Stock Titan Wed, 20 May 2026 11
- Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update - Quiver Quantitative Wed, 20 May 2026 14
- Immunovant to discuss 2026 results and business update on May 20 call - Stock Titan Mon, 11 May 2026 07
- IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance Mon, 06 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
532.90
+21.62%
|
438.15
+62.15%
|
270.21
+29.74%
|
208.28
|
| Research And Development |
|
456.66
+26.53%
|
360.92
+69.50%
|
212.93
+32.87%
|
160.26
|
| Selling General And Administration |
|
76.24
-1.29%
|
77.23
+34.84%
|
57.28
+19.29%
|
48.02
|
| General And Administrative Expense |
|
76.24
-1.29%
|
77.23
+34.84%
|
57.28
+19.29%
|
48.02
|
| Other Gand A |
|
76.24
-1.29%
|
77.23
+34.84%
|
57.28
+19.29%
|
48.02
|
| Total Expenses |
|
532.90
+21.62%
|
438.15
+62.15%
|
270.21
+29.74%
|
208.28
|
| Operating Income |
|
-532.90
-21.62%
|
-438.15
-62.15%
|
-270.21
-29.74%
|
-208.28
|
| EBITDA |
|
-532.49
-21.64%
|
-437.77
-62.15%
|
-269.98
-29.75%
|
-208.08
|
| Normalized EBITDA |
|
-532.49
-21.64%
|
-437.77
-70.02%
|
-257.48
-29.98%
|
-198.08
|
| Reconciled Depreciation |
|
0.41
+8.49%
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
|
| EBIT |
|
-532.90
-21.62%
|
-438.15
-62.15%
|
-270.21
-29.74%
|
-208.28
|
| Total Unusual Items |
|
0.00
|
0.00
+100.00%
|
-12.50
-25.00%
|
-10.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
|
0.00
+100.00%
|
-12.50
-25.00%
|
-10.00
|
| Special Income Charges |
|
0.00
|
0.00
+100.00%
|
-12.50
-25.00%
|
-10.00
|
| Other Special Charges |
|
—
|
—
|
12.50
+25.00%
|
10.00
|
| Restructuring And Mergern Acquisition |
|
0.00
|
0.00
-100.00%
|
12.50
+25.00%
|
10.00
|
| Net Income |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Pretax Income |
|
-505.39
-22.39%
|
-412.95
-59.58%
|
-258.77
-22.67%
|
-210.95
|
| Net Non Operating Interest Income Expense |
|
25.33
+2.42%
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
| Net Interest Income |
|
25.33
+2.42%
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
| Interest Income Non Operating |
|
25.33
+2.42%
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
| Interest Income |
|
25.33
+2.42%
|
24.73
-0.87%
|
24.95
+229.22%
|
7.58
|
| Other Income Expense |
|
2.18
+363.06%
|
0.47
+103.49%
|
-13.51
-31.75%
|
-10.25
|
| Other Non Operating Income Expenses |
|
2.18
+363.06%
|
0.47
+146.73%
|
-1.01
-298.42%
|
-0.25
|
| Tax Provision |
|
0.21
-75.87%
|
0.89
+57.14%
|
0.57
+6200.00%
|
0.01
|
| Tax Rate For Calcs |
|
0.00
+90.48%
|
0.00
+0.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-2.62
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Net Income From Continuing Operation Net Minority Interest |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Net Income From Continuing And Discontinued Operation |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Net Income Continuous Operations |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Normalized Income |
|
-505.61
-22.17%
|
-413.84
-65.89%
|
-249.46
-24.13%
|
-200.96
|
| Net Income Common Stockholders |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Diluted EPS |
|
—
|
-2.73
-45.21%
|
-1.88
-9.94%
|
-1.71
|
| Basic EPS |
|
—
|
-2.73
-45.21%
|
-1.88
-9.94%
|
-1.71
|
| Basic Average Shares |
|
—
|
151.57
+9.76%
|
138.10
+12.21%
|
123.08
|
| Diluted Average Shares |
|
—
|
151.57
+9.76%
|
138.10
+12.21%
|
123.08
|
| Diluted NI Availto Com Stockholders |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Line Item | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|---|
| Total Assets |
|
957.01
+23.29%
|
776.22
+16.49%
|
666.37
+64.19%
|
405.84
|
| Current Assets |
|
948.82
+23.60%
|
767.66
+15.30%
|
665.77
+64.66%
|
404.33
|
| Cash Cash Equivalents And Short Term Investments |
|
902.11
+26.35%
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
|
| Cash And Cash Equivalents |
|
902.11
+26.35%
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Receivables |
|
3.95
+57.15%
|
2.51
-54.37%
|
5.50
+521.81%
|
0.89
|
| Accounts Receivable |
|
1.13
-45.63%
|
2.08
-60.95%
|
5.34
+662.43%
|
0.70
|
| Taxes Receivable |
|
2.81
+558.78%
|
0.43
+157.23%
|
0.17
-10.27%
|
0.18
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
42.76
-16.45%
|
51.18
+105.53%
|
24.90
-7.48%
|
26.92
|
| Total Non Current Assets |
|
8.20
-4.26%
|
8.56
+1338.66%
|
0.59
-60.47%
|
1.50
|
| Net PPE |
|
0.52
-45.33%
|
0.94
+58.32%
|
0.59
-60.47%
|
1.50
|
| Gross PPE |
|
0.52
-45.33%
|
0.94
+58.32%
|
0.59
-60.47%
|
1.50
|
| Other Properties |
|
0.52
-45.33%
|
0.94
+58.32%
|
0.59
-60.47%
|
1.50
|
| Other Non Current Assets |
|
7.68
+0.81%
|
7.62
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
104.42
+51.83%
|
68.78
+41.49%
|
48.61
+12.14%
|
43.34
|
| Current Liabilities |
|
104.42
+51.83%
|
68.78
+41.49%
|
48.61
+12.27%
|
43.30
|
| Payables And Accrued Expenses |
|
87.58
+65.07%
|
53.06
+57.32%
|
33.73
-2.51%
|
34.59
|
| Payables |
|
7.72
-56.96%
|
17.93
+150.06%
|
7.17
+321.02%
|
1.70
|
| Accounts Payable |
|
7.54
-57.29%
|
17.66
+146.76%
|
7.16
+428.82%
|
1.35
|
| Current Accrued Expenses |
|
79.87
+127.35%
|
35.13
+32.29%
|
26.56
-19.26%
|
32.89
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
16.77
+7.36%
|
15.62
+5.93%
|
14.74
+95.80%
|
7.53
|
| Current Debt And Capital Lease Obligation |
|
0.07
-26.53%
|
0.10
-28.99%
|
0.14
-88.24%
|
1.17
|
| Current Capital Lease Obligation |
|
0.07
-26.53%
|
0.10
-28.99%
|
0.14
-88.24%
|
1.17
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.05
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.05
|
| Stockholders Equity |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Common Stock Equity |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Capital Stock |
|
0.02
+25.00%
|
0.02
+14.29%
|
0.01
+7.69%
|
0.01
|
| Common Stock |
|
0.02
+25.00%
|
0.02
+14.29%
|
0.01
+7.69%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
203.94
+19.89%
|
170.11
+16.85%
|
145.58
+11.70%
|
130.33
|
| Ordinary Shares Number |
|
203.94
+19.89%
|
170.11
+16.85%
|
145.58
+11.70%
|
130.33
|
| Additional Paid In Capital |
|
2,596.97
+33.49%
|
1,945.49
+34.96%
|
1,441.52
+55.34%
|
927.98
|
| Retained Earnings |
|
-1,745.13
-40.79%
|
-1,239.52
-50.12%
|
-825.68
-45.79%
|
-566.35
|
| Gains Losses Not Affecting Retained Earnings |
|
0.73
-49.97%
|
1.46
-23.53%
|
1.91
+123.94%
|
0.85
|
| Other Equity Adjustments |
|
0.73
-49.97%
|
1.46
-23.53%
|
1.91
+123.94%
|
0.85
|
| Total Equity Gross Minority Interest |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Total Capitalization |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Working Capital |
|
844.40
+20.82%
|
698.89
+13.24%
|
617.16
+70.94%
|
361.04
|
| Invested Capital |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Total Debt |
|
0.07
-26.53%
|
0.10
-28.99%
|
0.14
-88.69%
|
1.22
|
| Capital Lease Obligations |
|
0.07
-26.53%
|
0.10
-28.99%
|
0.14
-88.69%
|
1.22
|
| Net Tangible Assets |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Tangible Book Value |
|
852.59
+20.52%
|
707.45
+14.52%
|
617.76
+70.42%
|
362.49
|
| Dueto Related Parties Current |
|
0.17
-35.90%
|
0.27
+1720.00%
|
0.01
-95.71%
|
0.35
|
| Preferred Shares Number |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Line Item | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-407.31
-8.36%
|
-375.87
-75.46%
|
-214.23
-13.83%
|
-188.19
|
| Cash Flow From Continuing Operating Activities |
|
-407.31
-8.36%
|
-375.87
-75.46%
|
-214.23
-13.83%
|
-188.19
|
| Net Income From Continuing Operations |
|
-505.61
-22.17%
|
-413.84
-59.58%
|
-259.34
-22.93%
|
-210.96
|
| Depreciation Amortization Depletion |
|
0.41
+8.49%
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
|
| Depreciation |
|
0.41
+8.49%
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
|
| Depreciation And Amortization |
|
0.41
+8.49%
|
0.38
+63.20%
|
0.23
+19.69%
|
0.19
|
| Other Non Cash Items |
|
0.10
-25.56%
|
0.13
-88.23%
|
1.13
-0.09%
|
1.13
|
| Stock Based Compensation |
|
55.72
+12.60%
|
49.49
+20.36%
|
41.12
+27.31%
|
32.30
|
| Change In Working Capital |
|
42.06
+449.63%
|
-12.03
-557.10%
|
2.63
+124.25%
|
-10.85
|
| Change In Receivables |
|
-1.40
-147.12%
|
2.97
+165.18%
|
-4.56
-137.28%
|
12.22
|
| Changes In Account Receivables |
|
0.99
-69.49%
|
3.23
+170.61%
|
-4.58
-138.91%
|
11.76
|
| Change In Prepaid Assets |
|
8.84
+132.77%
|
-26.99
-1832.35%
|
1.56
+107.59%
|
-20.53
|
| Change In Payables And Accrued Expense |
|
34.65
+74.45%
|
19.86
+191.92%
|
6.80
+586.00%
|
-1.40
|
| Change In Accrued Expense |
|
45.00
+404.31%
|
8.92
+561.45%
|
1.35
-91.33%
|
15.57
|
| Change In Payable |
|
-10.35
-194.62%
|
10.94
+100.53%
|
5.46
+132.15%
|
-16.97
|
| Change In Account Payable |
|
-10.25
-195.96%
|
10.68
+84.72%
|
5.78
+133.78%
|
-17.12
|
| Change In Other Current Assets |
|
0.07
+100.89%
|
-7.74
|
0.00
|
0.00
|
| Change In Other Current Liabilities |
|
-0.10
+28.26%
|
-0.14
+88.23%
|
-1.17
-2.36%
|
-1.15
|
| Investing Cash Flow |
|
-0.01
+98.95%
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
+98.95%
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
|
| Net PPE Purchase And Sale |
|
-0.01
+98.95%
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
|
| Purchase Of PPE |
|
-0.01
+98.95%
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
|
| Capital Expenditure |
|
-0.01
+98.95%
|
-0.76
-110.83%
|
-0.36
-82.74%
|
-0.20
|
| Financing Cash Flow |
|
595.76
+31.08%
|
454.49
-3.80%
|
472.43
+566.47%
|
70.89
|
| Cash Flow From Continuing Financing Activities |
|
595.76
+31.08%
|
454.49
-3.80%
|
472.43
+566.47%
|
70.89
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Repayment Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
544.19
+20.93%
|
450.00
-4.81%
|
472.75
+570.56%
|
70.50
|
| Proceeds From Stock Option Exercised |
|
52.07
+982.23%
|
4.81
-15.51%
|
5.69
+766.67%
|
0.66
|
| Net Other Financing Charges |
|
-0.50
-57.99%
|
-0.32
+94.69%
|
-6.01
-2110.29%
|
-0.27
|
| Changes In Cash |
|
188.44
+142.02%
|
77.86
-69.80%
|
257.84
+319.43%
|
-117.50
|
| Effect Of Exchange Rate Changes |
|
-0.30
-140.03%
|
0.75
-24.77%
|
0.99
+351.36%
|
0.22
|
| Beginning Cash Position |
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
-23.75%
|
493.82
|
| End Cash Position |
|
902.11
+26.35%
|
713.97
+12.37%
|
635.37
+68.74%
|
376.53
|
| Free Cash Flow |
|
-407.32
-8.15%
|
-376.63
-75.52%
|
-214.59
-13.91%
|
-188.39
|
| Income Tax Paid Supplemental Data |
|
2.39
+98.50%
|
1.20
+136.15%
|
0.51
|
0.00
|
| Common Stock Issuance |
|
544.19
+20.93%
|
450.00
-4.81%
|
472.75
+570.56%
|
70.50
|
| Issuance Of Capital Stock |
|
544.19
+20.93%
|
450.00
-4.81%
|
472.75
+570.56%
|
70.50
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-05-29 View
- 42026-05-22 View
- 42026-05-20 View
- 10-K2026-05-20 View
- 8-K2026-05-20 View
- 42026-05-01 View
- 42026-04-24 View
- 42026-04-24 View
- 42026-04-10 View
- 42026-04-10 View
- 42026-04-10 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
- 42026-04-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|